(−)‐o‐[11C]methyl‐trans‐decalinvesamicol ((−)‐[11C]OMDV) as a PET ligand for the vesicular acetylcholine transporter
To develop a PET imaging agent to visualize brain cholinergic neurons and synaptic changes caused by Alzheimer's disease, (−)‐ and (+)‐o‐[11C]methyl‐trans‐decalinvesamicol ([11C]OMDV) were isolated and investigated for differences in not only their binding affinity and selectivity to vesicular...
Gespeichert in:
Veröffentlicht in: | Synapse (New York, N.Y.) N.Y.), 2020-11, Vol.74 (11), p.e22176-n/a |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 11 |
container_start_page | e22176 |
container_title | Synapse (New York, N.Y.) |
container_volume | 74 |
creator | Miwa, Daisuke Kitamura, Yoji Kozaka, Takashi Shigeno, Taiki Ogawa, Kazuma Taki, Junichi Kinuya, Seigo Shiba, Kazuhiro |
description | To develop a PET imaging agent to visualize brain cholinergic neurons and synaptic changes caused by Alzheimer's disease, (−)‐ and (+)‐o‐[11C]methyl‐trans‐decalinvesamicol ([11C]OMDV) were isolated and investigated for differences in not only their binding affinity and selectivity to vesicular acetylcholine transporter (VAChT), but also their in vivo activities. [11C]OMDV has a high binding affinity for VAChT both in vitro and in vivo. Racemic OMDV and o‐trimethylstannyl‐trans‐decalinvesamicol (OTDV), which are precursors for synthesis of [11C]OMDV, were separated into (−)‐optical isomers ((−)‐OMDV and (−)‐OTDV) and (+)‐optical isomers ((+)‐OMDV and (+)‐OTDV) by HPLC. In the in vitro binding assay, (−)‐OMDV(7.2 nM) showed eight times higher binding affinity (Ki) to VAChT than that of (+)‐OMDV(57.5 nM). In the biodistribution study, the blood–brain barrier permeability of both enantiomers ((−)‐[11C]OMDV and (+)‐[11C]OMDV) was similarly high (about 1.0%ID/g) at 2 min post‐injection. However, (+)‐[11C]OMDV clearance from the brain was faster than (−)‐[11C]OMDV. In the in vivo blocking study, accumulation of (−)‐[11C]OMDV in the cortex was markedly decreased (approximately 30% of control) by coadministration of vesamicol, and brain uptake of (−)‐[11C]OMDV was not significantly altered by coadministration of (+)‐pentazocine or (+)‐3‐(3‐hydroxyphenyl)‐N‐propylpiperidine ((+)‐3‐PPP). PET‐CT imaging revealed inhibition of the rat brain uptake of (−)‐[11C]OMDV by coadministration of vesamicol. In conclusion, (−)‐[11C]OMDV, which is an enantiomer of OMDV, selectively binds to VAChT with high affinity in the rat brain in vivo. (−)‐[11C]OMDV may be utilized as a potential PET ligand for studying presynaptic cholinergic neurons in the brain.
(−)‐[11C]OMDV was evaluated in in vivo for PET imaging vesicular acetylcholine transporter (VAChT), located in the presynaptic cholinergic terminals of brain. High and selective accumulation (−)‐[11C]OMDV to VAChT in rat brain revealed the possibility of (−)‐[11C]OMDV to be a prospective VAChT PET ligand. |
doi_str_mv | 10.1002/syn.22176 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2410359837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2410359837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3966-23626ed6931dd938f69ef033e41505dd533fa2cc0dbb007a59dd2c5efb7fbb553</originalsourceid><addsrcrecordid>eNp1kU9LJDEQxYOs4KzuwW8Q2MvMYbTS6XR3jjL-BVcF3YVlkSadVDstmc6Y9Ch9E097FD-in8Q4s16EPRRFwe896vEI2WawwwCS3dC3O0nC8myNDBjIYpxwmX0hAyiKfJymebZBvoZwCwCcQTogT8PXvy-j18dnF-cPY5PrGXbT3sar86oNcRvUyjbtPQY1a7SzdPihWfLnP_Z_jagKVNGLgytqmxvVGlo7T7sp0qhq9MIqT5XGrrd66qIX0qX53PkO_RZZr5UN-O3f3iQ_Dw-uJsfj0_Ojk8ne6VjHCFkMkiUZmkxyZozkRZ1JrIFzTJkAYYzgvFaJ1mCqCiBXQhqTaIF1lddVJQTfJMOV79y7uwWGrpw1QaO1qkW3CGWSMuBCFjyP6PdP6K1b-DZ-F6mUMSElh0iNVpT2LgSPdTn3zUz5vmRQvrdRxjbKZRuR3V2xD43F_v9gefn7bKV4Axiskdo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441159930</pqid></control><display><type>article</type><title>(−)‐o‐[11C]methyl‐trans‐decalinvesamicol ((−)‐[11C]OMDV) as a PET ligand for the vesicular acetylcholine transporter</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Miwa, Daisuke ; Kitamura, Yoji ; Kozaka, Takashi ; Shigeno, Taiki ; Ogawa, Kazuma ; Taki, Junichi ; Kinuya, Seigo ; Shiba, Kazuhiro</creator><creatorcontrib>Miwa, Daisuke ; Kitamura, Yoji ; Kozaka, Takashi ; Shigeno, Taiki ; Ogawa, Kazuma ; Taki, Junichi ; Kinuya, Seigo ; Shiba, Kazuhiro</creatorcontrib><description>To develop a PET imaging agent to visualize brain cholinergic neurons and synaptic changes caused by Alzheimer's disease, (−)‐ and (+)‐o‐[11C]methyl‐trans‐decalinvesamicol ([11C]OMDV) were isolated and investigated for differences in not only their binding affinity and selectivity to vesicular acetylcholine transporter (VAChT), but also their in vivo activities. [11C]OMDV has a high binding affinity for VAChT both in vitro and in vivo. Racemic OMDV and o‐trimethylstannyl‐trans‐decalinvesamicol (OTDV), which are precursors for synthesis of [11C]OMDV, were separated into (−)‐optical isomers ((−)‐OMDV and (−)‐OTDV) and (+)‐optical isomers ((+)‐OMDV and (+)‐OTDV) by HPLC. In the in vitro binding assay, (−)‐OMDV(7.2 nM) showed eight times higher binding affinity (Ki) to VAChT than that of (+)‐OMDV(57.5 nM). In the biodistribution study, the blood–brain barrier permeability of both enantiomers ((−)‐[11C]OMDV and (+)‐[11C]OMDV) was similarly high (about 1.0%ID/g) at 2 min post‐injection. However, (+)‐[11C]OMDV clearance from the brain was faster than (−)‐[11C]OMDV. In the in vivo blocking study, accumulation of (−)‐[11C]OMDV in the cortex was markedly decreased (approximately 30% of control) by coadministration of vesamicol, and brain uptake of (−)‐[11C]OMDV was not significantly altered by coadministration of (+)‐pentazocine or (+)‐3‐(3‐hydroxyphenyl)‐N‐propylpiperidine ((+)‐3‐PPP). PET‐CT imaging revealed inhibition of the rat brain uptake of (−)‐[11C]OMDV by coadministration of vesamicol. In conclusion, (−)‐[11C]OMDV, which is an enantiomer of OMDV, selectively binds to VAChT with high affinity in the rat brain in vivo. (−)‐[11C]OMDV may be utilized as a potential PET ligand for studying presynaptic cholinergic neurons in the brain.
(−)‐[11C]OMDV was evaluated in in vivo for PET imaging vesicular acetylcholine transporter (VAChT), located in the presynaptic cholinergic terminals of brain. High and selective accumulation (−)‐[11C]OMDV to VAChT in rat brain revealed the possibility of (−)‐[11C]OMDV to be a prospective VAChT PET ligand.</description><identifier>ISSN: 0887-4476</identifier><identifier>EISSN: 1098-2396</identifier><identifier>DOI: 10.1002/syn.22176</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc</publisher><subject>Acetylcholine ; Affinity ; Alzheimer's disease ; Blood-brain barrier ; Computed tomography ; Enantiomers ; High-performance liquid chromatography ; imaging probe ; Isomers ; Ligands ; Membrane permeability ; Neurodegenerative diseases ; Neuroimaging ; Pentazocine ; PET ; Positron emission tomography ; VAChT ; Vesamicol ; vesamicol analog ; Vesicular acetylcholine transporter</subject><ispartof>Synapse (New York, N.Y.), 2020-11, Vol.74 (11), p.e22176-n/a</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3966-23626ed6931dd938f69ef033e41505dd533fa2cc0dbb007a59dd2c5efb7fbb553</citedby><cites>FETCH-LOGICAL-c3966-23626ed6931dd938f69ef033e41505dd533fa2cc0dbb007a59dd2c5efb7fbb553</cites><orcidid>0000-0001-8323-1004 ; 0000-0002-1691-7302 ; 0000-0001-7120-0200</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fsyn.22176$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fsyn.22176$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27911,27912,45561,45562</link.rule.ids></links><search><creatorcontrib>Miwa, Daisuke</creatorcontrib><creatorcontrib>Kitamura, Yoji</creatorcontrib><creatorcontrib>Kozaka, Takashi</creatorcontrib><creatorcontrib>Shigeno, Taiki</creatorcontrib><creatorcontrib>Ogawa, Kazuma</creatorcontrib><creatorcontrib>Taki, Junichi</creatorcontrib><creatorcontrib>Kinuya, Seigo</creatorcontrib><creatorcontrib>Shiba, Kazuhiro</creatorcontrib><title>(−)‐o‐[11C]methyl‐trans‐decalinvesamicol ((−)‐[11C]OMDV) as a PET ligand for the vesicular acetylcholine transporter</title><title>Synapse (New York, N.Y.)</title><description>To develop a PET imaging agent to visualize brain cholinergic neurons and synaptic changes caused by Alzheimer's disease, (−)‐ and (+)‐o‐[11C]methyl‐trans‐decalinvesamicol ([11C]OMDV) were isolated and investigated for differences in not only their binding affinity and selectivity to vesicular acetylcholine transporter (VAChT), but also their in vivo activities. [11C]OMDV has a high binding affinity for VAChT both in vitro and in vivo. Racemic OMDV and o‐trimethylstannyl‐trans‐decalinvesamicol (OTDV), which are precursors for synthesis of [11C]OMDV, were separated into (−)‐optical isomers ((−)‐OMDV and (−)‐OTDV) and (+)‐optical isomers ((+)‐OMDV and (+)‐OTDV) by HPLC. In the in vitro binding assay, (−)‐OMDV(7.2 nM) showed eight times higher binding affinity (Ki) to VAChT than that of (+)‐OMDV(57.5 nM). In the biodistribution study, the blood–brain barrier permeability of both enantiomers ((−)‐[11C]OMDV and (+)‐[11C]OMDV) was similarly high (about 1.0%ID/g) at 2 min post‐injection. However, (+)‐[11C]OMDV clearance from the brain was faster than (−)‐[11C]OMDV. In the in vivo blocking study, accumulation of (−)‐[11C]OMDV in the cortex was markedly decreased (approximately 30% of control) by coadministration of vesamicol, and brain uptake of (−)‐[11C]OMDV was not significantly altered by coadministration of (+)‐pentazocine or (+)‐3‐(3‐hydroxyphenyl)‐N‐propylpiperidine ((+)‐3‐PPP). PET‐CT imaging revealed inhibition of the rat brain uptake of (−)‐[11C]OMDV by coadministration of vesamicol. In conclusion, (−)‐[11C]OMDV, which is an enantiomer of OMDV, selectively binds to VAChT with high affinity in the rat brain in vivo. (−)‐[11C]OMDV may be utilized as a potential PET ligand for studying presynaptic cholinergic neurons in the brain.
(−)‐[11C]OMDV was evaluated in in vivo for PET imaging vesicular acetylcholine transporter (VAChT), located in the presynaptic cholinergic terminals of brain. High and selective accumulation (−)‐[11C]OMDV to VAChT in rat brain revealed the possibility of (−)‐[11C]OMDV to be a prospective VAChT PET ligand.</description><subject>Acetylcholine</subject><subject>Affinity</subject><subject>Alzheimer's disease</subject><subject>Blood-brain barrier</subject><subject>Computed tomography</subject><subject>Enantiomers</subject><subject>High-performance liquid chromatography</subject><subject>imaging probe</subject><subject>Isomers</subject><subject>Ligands</subject><subject>Membrane permeability</subject><subject>Neurodegenerative diseases</subject><subject>Neuroimaging</subject><subject>Pentazocine</subject><subject>PET</subject><subject>Positron emission tomography</subject><subject>VAChT</subject><subject>Vesamicol</subject><subject>vesamicol analog</subject><subject>Vesicular acetylcholine transporter</subject><issn>0887-4476</issn><issn>1098-2396</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kU9LJDEQxYOs4KzuwW8Q2MvMYbTS6XR3jjL-BVcF3YVlkSadVDstmc6Y9Ch9E097FD-in8Q4s16EPRRFwe896vEI2WawwwCS3dC3O0nC8myNDBjIYpxwmX0hAyiKfJymebZBvoZwCwCcQTogT8PXvy-j18dnF-cPY5PrGXbT3sar86oNcRvUyjbtPQY1a7SzdPihWfLnP_Z_jagKVNGLgytqmxvVGlo7T7sp0qhq9MIqT5XGrrd66qIX0qX53PkO_RZZr5UN-O3f3iQ_Dw-uJsfj0_Ojk8ne6VjHCFkMkiUZmkxyZozkRZ1JrIFzTJkAYYzgvFaJ1mCqCiBXQhqTaIF1lddVJQTfJMOV79y7uwWGrpw1QaO1qkW3CGWSMuBCFjyP6PdP6K1b-DZ-F6mUMSElh0iNVpT2LgSPdTn3zUz5vmRQvrdRxjbKZRuR3V2xD43F_v9gefn7bKV4Axiskdo</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Miwa, Daisuke</creator><creator>Kitamura, Yoji</creator><creator>Kozaka, Takashi</creator><creator>Shigeno, Taiki</creator><creator>Ogawa, Kazuma</creator><creator>Taki, Junichi</creator><creator>Kinuya, Seigo</creator><creator>Shiba, Kazuhiro</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8323-1004</orcidid><orcidid>https://orcid.org/0000-0002-1691-7302</orcidid><orcidid>https://orcid.org/0000-0001-7120-0200</orcidid></search><sort><creationdate>202011</creationdate><title>(−)‐o‐[11C]methyl‐trans‐decalinvesamicol ((−)‐[11C]OMDV) as a PET ligand for the vesicular acetylcholine transporter</title><author>Miwa, Daisuke ; Kitamura, Yoji ; Kozaka, Takashi ; Shigeno, Taiki ; Ogawa, Kazuma ; Taki, Junichi ; Kinuya, Seigo ; Shiba, Kazuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3966-23626ed6931dd938f69ef033e41505dd533fa2cc0dbb007a59dd2c5efb7fbb553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acetylcholine</topic><topic>Affinity</topic><topic>Alzheimer's disease</topic><topic>Blood-brain barrier</topic><topic>Computed tomography</topic><topic>Enantiomers</topic><topic>High-performance liquid chromatography</topic><topic>imaging probe</topic><topic>Isomers</topic><topic>Ligands</topic><topic>Membrane permeability</topic><topic>Neurodegenerative diseases</topic><topic>Neuroimaging</topic><topic>Pentazocine</topic><topic>PET</topic><topic>Positron emission tomography</topic><topic>VAChT</topic><topic>Vesamicol</topic><topic>vesamicol analog</topic><topic>Vesicular acetylcholine transporter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miwa, Daisuke</creatorcontrib><creatorcontrib>Kitamura, Yoji</creatorcontrib><creatorcontrib>Kozaka, Takashi</creatorcontrib><creatorcontrib>Shigeno, Taiki</creatorcontrib><creatorcontrib>Ogawa, Kazuma</creatorcontrib><creatorcontrib>Taki, Junichi</creatorcontrib><creatorcontrib>Kinuya, Seigo</creatorcontrib><creatorcontrib>Shiba, Kazuhiro</creatorcontrib><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Synapse (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miwa, Daisuke</au><au>Kitamura, Yoji</au><au>Kozaka, Takashi</au><au>Shigeno, Taiki</au><au>Ogawa, Kazuma</au><au>Taki, Junichi</au><au>Kinuya, Seigo</au><au>Shiba, Kazuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>(−)‐o‐[11C]methyl‐trans‐decalinvesamicol ((−)‐[11C]OMDV) as a PET ligand for the vesicular acetylcholine transporter</atitle><jtitle>Synapse (New York, N.Y.)</jtitle><date>2020-11</date><risdate>2020</risdate><volume>74</volume><issue>11</issue><spage>e22176</spage><epage>n/a</epage><pages>e22176-n/a</pages><issn>0887-4476</issn><eissn>1098-2396</eissn><abstract>To develop a PET imaging agent to visualize brain cholinergic neurons and synaptic changes caused by Alzheimer's disease, (−)‐ and (+)‐o‐[11C]methyl‐trans‐decalinvesamicol ([11C]OMDV) were isolated and investigated for differences in not only their binding affinity and selectivity to vesicular acetylcholine transporter (VAChT), but also their in vivo activities. [11C]OMDV has a high binding affinity for VAChT both in vitro and in vivo. Racemic OMDV and o‐trimethylstannyl‐trans‐decalinvesamicol (OTDV), which are precursors for synthesis of [11C]OMDV, were separated into (−)‐optical isomers ((−)‐OMDV and (−)‐OTDV) and (+)‐optical isomers ((+)‐OMDV and (+)‐OTDV) by HPLC. In the in vitro binding assay, (−)‐OMDV(7.2 nM) showed eight times higher binding affinity (Ki) to VAChT than that of (+)‐OMDV(57.5 nM). In the biodistribution study, the blood–brain barrier permeability of both enantiomers ((−)‐[11C]OMDV and (+)‐[11C]OMDV) was similarly high (about 1.0%ID/g) at 2 min post‐injection. However, (+)‐[11C]OMDV clearance from the brain was faster than (−)‐[11C]OMDV. In the in vivo blocking study, accumulation of (−)‐[11C]OMDV in the cortex was markedly decreased (approximately 30% of control) by coadministration of vesamicol, and brain uptake of (−)‐[11C]OMDV was not significantly altered by coadministration of (+)‐pentazocine or (+)‐3‐(3‐hydroxyphenyl)‐N‐propylpiperidine ((+)‐3‐PPP). PET‐CT imaging revealed inhibition of the rat brain uptake of (−)‐[11C]OMDV by coadministration of vesamicol. In conclusion, (−)‐[11C]OMDV, which is an enantiomer of OMDV, selectively binds to VAChT with high affinity in the rat brain in vivo. (−)‐[11C]OMDV may be utilized as a potential PET ligand for studying presynaptic cholinergic neurons in the brain.
(−)‐[11C]OMDV was evaluated in in vivo for PET imaging vesicular acetylcholine transporter (VAChT), located in the presynaptic cholinergic terminals of brain. High and selective accumulation (−)‐[11C]OMDV to VAChT in rat brain revealed the possibility of (−)‐[11C]OMDV to be a prospective VAChT PET ligand.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/syn.22176</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8323-1004</orcidid><orcidid>https://orcid.org/0000-0002-1691-7302</orcidid><orcidid>https://orcid.org/0000-0001-7120-0200</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0887-4476 |
ispartof | Synapse (New York, N.Y.), 2020-11, Vol.74 (11), p.e22176-n/a |
issn | 0887-4476 1098-2396 |
language | eng |
recordid | cdi_proquest_miscellaneous_2410359837 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | Acetylcholine Affinity Alzheimer's disease Blood-brain barrier Computed tomography Enantiomers High-performance liquid chromatography imaging probe Isomers Ligands Membrane permeability Neurodegenerative diseases Neuroimaging Pentazocine PET Positron emission tomography VAChT Vesamicol vesamicol analog Vesicular acetylcholine transporter |
title | (−)‐o‐[11C]methyl‐trans‐decalinvesamicol ((−)‐[11C]OMDV) as a PET ligand for the vesicular acetylcholine transporter |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T01%3A43%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=(%E2%88%92)%E2%80%90o%E2%80%90%5B11C%5Dmethyl%E2%80%90trans%E2%80%90decalinvesamicol%20((%E2%88%92)%E2%80%90%5B11C%5DOMDV)%20as%20a%20PET%20ligand%20for%20the%20vesicular%20acetylcholine%20transporter&rft.jtitle=Synapse%20(New%20York,%20N.Y.)&rft.au=Miwa,%20Daisuke&rft.date=2020-11&rft.volume=74&rft.issue=11&rft.spage=e22176&rft.epage=n/a&rft.pages=e22176-n/a&rft.issn=0887-4476&rft.eissn=1098-2396&rft_id=info:doi/10.1002/syn.22176&rft_dat=%3Cproquest_cross%3E2410359837%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2441159930&rft_id=info:pmid/&rfr_iscdi=true |